Platelet Society Meeting 2024
Platelet Services is sponsoring and will be exhibiting at the Platelet Society Meeting 2024 on 24-26 April at P&J Live in Aberdeen. The Platelet Society will bring together both senior and junior scientists in an informal setting to discuss the latest research in platelets and megakaryocyte biology. This will range from basic science to recent […]
American College of Toxicology (ACT) 44th Annual Meeting
The Platelet Services team will be attending and exhibiting at the ACT 44th Annual Meeting on the 12-15 November in Orlando, Florida, at the Rosen Shingle Creek Hotel. ACT brings together a community of scientists from pharmaceutical and biotech industries, regulatory agencies, CROs, academia, and R&D consultants. The highly anticipated Annual Meeting has a line-up […]
6th EUPLAN International Conference
Platelet Services will be attending the 6th EUPLAN International Conference, taking place at the University of Bristol on September 4-6 2023. EUPLAN 2023 is a prestigious event organised by the Platelet Society annually. The conference aims to provide a platform for researchers, clinicians, and industry experts to exchange knowledge, present cutting-edge research findings, and explore […]
BTS Discovery Toxicology 2023
Platelet Services will be attending BTS Discovery Toxicology 2023 “What’s new from small molecules to cell and gene therapies” on Wednesday 14th June at the Alderley Park Conference Centre. The one-day meeting will showcase strategies that are enabling more efficient and robust approaches to achieve success in drug discovery and development. Paul Cato, Senior Research Scientist, […]
WCP 2023 – 19th World Congress of Basic & Clinical Pharmacology
The Platelet Services team will be attending and exhibiting at the 19th World Congress of Basic & Clinical Pharmacology (WCP2023) on 2nd – 7th July at the Scottish Event Campus (SEC) in Glasgow, Scotland. The congress will bring together the global pharmacology and therapeutics community to discuss the latest cutting-edge science. The extensive programme includes […]
ELRIG Therapeutic OLIGO and European Chemical Biology Symposium 2023
Platelet Services will be attending the ELRIG meeting on Therapeutic OLIGOs combined with the 8th European Chemical Biology Symposium (ECBS) on May 9-11 at the AstraZeneca R&D site in Gothenburg. The three-day event will discuss the recent advancements in the discovery of therapeutic OLIGOs and in the Chemical Biology research field in Europe and across […]
Platelet Services to sponsor Platelet Society “Platelets and Neurovascular Disease” Meeting
The Platelet Society is hosting a free online meeting titled “Platelets and Neurovascular Disease” from 1pm – 5pm on Wednesday 19th October. The meeting will bringing together platelet and neurovascular researchers to discuss the contributions platelets make to neurovascular disease and other related conditions including vascular dementia and Alzheimer’s. The meeting includes a great programme […]
ELRIG Drug Discovery 2022
The Platelet Services team will be attending ELRIG Drug Discovery 2022 on the 4-5 October 2022 in London. The two-day event is Europe’s largest meeting for life sciences industry professionals and provides a platform for the drug discovery community to meet, network and collaborate. Natalia Dovlatova (CEO), Wendy Tomlinson (CSO), Bob Humphries (Non-Executive Director, Drug […]
5th EUPLAN International Conference
Platelet Services will be attending the 5th EUPLAN International Conference, taking place at the University of Milan on September 28-30 2022. From the Platelet Services team, Paul Cato (Senior Research Scientist) and Charlotte Jewell (Research Scientist) will be in attendance. The meeting will bring together senior scientists and young fellows to discuss a broad range […]
BTS Discovery Toxicology 2022
Platelet Services will be attending the BTS Discovery Toxicology 2022 meeting at Alderley Park on 15 June. The one-day meeting will showcase the strategies enabling efficient and robust approaches to help maximise drug discovery and development success. With safety risks being a major cause of drug discovery and development attrition, the use of a carefully […]
